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Protein tyrosine phosphatase 1B (PTP1B) plays
important roles in downregulation of insulin and
leptin signaling and is an established therapeutic
target for diabetes and obesity. PTP1B is regulated
by reactive oxygen species (ROS) produced in
response to various stimuli, including insulin. The
reversibly oxidized form of the enzyme (PTP1B-OX)
is inactive and undergoes profound conformational
changes at the active site. We generated conforma-
tion-sensor antibodies, in the form of single-chain
variable fragments (scFvs), that stabilize PTP1B-OX
and thereby inhibit its phosphatase function. Expres-
sion of conformation-sensor scFvs as intracellular
antibodies (intrabodies) enhanced insulin-induced
tyrosyl phosphorylation of the b subunit of the insulin
receptor and its substrate IRS-1 and increased
insulin-induced phosphorylation of PKB/AKT. Our
data suggest that stabilization of the oxidized, inac-
tive form of PTP1B with appropriate therapeutic
molecules may offer a paradigm for phosphatase
drug development.INTRODUCTION
In conjunctionwith the increased prevalence of obesity, diabetes
has become a major cause of illness and premature death in
most countries, mainly through the increased risk of cardiovas-
cular disease. Type 2 diabetes, which is caused by insulin resis-
tance resulting in loss of normal glucose homeostasis, accounts
for >90% of all diabetes. It affects more than 220 million people
worldwide, and this number is likely to double by 2030 (WHO,
2009). At this time therapeutic options for treating diabetes and
obesity are inadequate, and effective approaches to counter
the disease are urgently needed.Considerable interest grew in the potential of protein tyrosine
phosphatase 1B (PTP1B) as a therapeutic target for treating
diabetes and obesity following the elucidation of its importance
as a regulator of insulin and leptin signaling pathways. Gene-tar-
geting studies demonstrated that PTP1B null mice are healthy,
do not develop type 2 diabetes, and are resistant to obesity
when fed with a high-fat diet (Elchebly et al., 1999; Klaman
et al., 2000). PTP1B is also an inhibitor of leptin signaling (Cheng
et al., 2002; Myers et al., 2001; Zabolotny et al., 2002). Further-
more, depletion of PTP1B expression with antisense oligonucle-
otides elicits antidiabetic and antiobesity effects in rodents
(Rondinone et al., 2002; Zinker et al., 2002) as well as human
subjects (Brandt et al., 2010).
PTP1B was the first member of the protein tyrosine phospha-
tase (PTP) superfamily to be identified and was purified to homo-
geneity from human placenta as a catalytic domain of 37 kDa
(Tonks et al., 1988). Later, it was characterized as an 50 kDa
protein (435 amino acids), consisting of an N-terminal catalytic
domain followed by a C-terminal segment that serves a regula-
tory function and anchors the protein at the cytoplasmic face
of the endoplasmic reticulum (ER) membrane (Tonks, 2003). It
contains a signature catalytic motif, (I/V)HCXAGXXR(S/T)G,
which is a highly conserved structural feature among PTPs, in
which Cys215 and Arg221 are essential for catalytic activity
(Tonks, 2003). PTP1B recognizes the activated insulin receptor
as a substrate in vitro and in cells (Bandyopadhyay et al.,
1997; Salmeen et al., 2000). Crystal structure and kinetic studies
illustrate that PTP1B preferentially dephosphorylates the tandem
tyrosine residues (pYpY1162/1163) in the activation loop of
the b subunit of the insulin receptor (Salmeen et al., 2000). In
addition, insulin receptor substrate-1 (IRS-1) is also a potential
substrate of PTP1B (Goldstein et al., 2000). Hence, PTP1B func-
tions to downregulate insulin signaling.
The activity of PTP1B is regulated at multiple levels. The archi-
tecture of the PTP-active site is such that the cysteinyl residue
has a pKa of 4.5–5.0 and is predominantly in the thiolate form
at neutral pH, unlike the normal pKa of cysteine, which is 8
(Lohse et al., 1997). This property makes the active-site cysteine
a very good nucleophile but also renders it prone to oxidation.Cell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc. 185
Several labs have demonstrated that PTPs, including PTP1B,
are transiently oxidized and reversibly inactivated by H2O2, and
that this is important for induction of an optimal tyrosine phos-
phorylation response to a variety of physiological stimuli (Lee
et al., 2002; Meng et al., 2002; Savitsky and Finkel, 2002). Insulin
stimulation of mammalian cells leads to enhanced production
of intracellular H2O2, which causes reversible oxidization and
inhibition of PTP1B activity (Mahadev et al., 2001; Meng et al.,
2004). Nox4, a member of the family of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases, was shown to
mediate insulin-stimulated H2O2 generation and to regulate the
insulin signaling cascade (Mahadev et al., 2004). Understanding
the redox regulation of PTPs in a cellular context has been
hampered by the absence of sensitive and robust methods
for detecting the oxidized phosphatases and separating
them from the background of reduced enzymes. Using antibody
phage display, we have generated conformation-sensor anti-
bodies in the form of single-chain variable fragments (scFvs)
to the reversibly oxidized form of PTP1B (PTP1B-OX) and
applied them to understand the redox regulation of this
phosphatase.
Mild oxidation of the active-site cysteine of PTP1B produces
a sulfenic acid (S-OH) intermediate that undergoes a rapid
condensation reaction to produce a 5-atom cyclic sulfenyl-
amide species, in which the sulfur atom of the catalytic cysteine
is covalently linked to the main-chain nitrogen of the adjacent
serine residue (Salmeen et al., 2003; van Montfort et al., 2003).
Formation of this sulfenyl-amide intermediate causes profound
conformational changes in the active site that transiently inhibit
substrate binding and catalysis. These structural changes,
however, are reversible under reducing conditions. In order to
maintain reversibility, the active-site Cys residue should be
oxidized no further than sulfenic acid (S-OH), as higher oxidation
to sulfinic (S-O2H) or sulfonic (S-O3H) acid is generally irrevers-
ible (Salmeen et al., 2003; van Montfort et al., 2003). The chem-
ical change at the core of the catalytic site is accompanied by
a conformational change in which the PTP loop containing the
signature motif and Tyr46 of the phosphotyrosine loop, which
are both normally buried in the structure, now adopt solvent-
exposed positions. We hypothesized that a conformation-
sensor antibody that recognizes the reversibly oxidized form of
PTP1B (PTP1B-OX) may stabilize the inactive state and thereby
inhibit phosphatase activity.
We have exploited the fact that a mutant form of PTP1B
(CASA), in which the catalytic Cys and adjacent Ser residues
are mutated to Ala, adopts a stable conformation that is identical
to PTP1B-OX. We have used this as an antigen, and in this
report, we describe the characterization of conformation-sensor
scFvs that recognize the reversibly oxidized form of PTP1B and
stabilize the inactive state to inhibit its reactivation by reducing
agent. Using the conformation sensor scFvs as intracellular
antibodies or ‘‘intrabodies,’’ we have demonstrated that the
activity of PTP1B can be attenuated selectively by stabilizing
its reversibly oxidized conformation in cells in response to
insulin-induced production of reactive oxygen species (ROS).
This results in enhanced and sustained signaling in response
to insulin, suggesting that this strategy may provide an alterna-
tive approach to the design of PTP-directed inhibitors.186 Cell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc.RESULTS
PTP1B-CASA Is Structurally Similar to PTP1B-OX
From comparative analysis of the crystal structure of PTP1B in
the reduced and oxidized states (cyclic sulfenyl-amide), we
hypothesized that mutation of both the catalytic Cys215 and
the adjacent Ser216 to Ala would break two critical hydrogen
bonds and thereby may induce a conformational change similar
to the effects of oxidation. The crystal structure of the mutated
PTP1B (PTP1B-CASA) illustrated that the Tyr46 of the pTyr
loop became solvent exposed, and the PTP loop was also pre-
sented on the protein surface as seen in the oxidized enzyme
(Figure 1 and Table S1 available online). PTP1B-CASA was,
therefore, used as a stable antigen to generate conformation-
specific antibodies to test their potential to specifically recognize
the oxidized form of PTP1B.
Construction of Antibody Phage Display Library
to Target PTP1B-OX
We have generated a phage display library displaying scFvs
fused to phage surface protein pIII (Figure 2A and Figure S1),
from antibody genes collected from chickens immunized with
PTP1B-CASA. We generated two different scFv constructs,
one with a short linker sequence (GQSSRSS) and one with a
long linker (GQSSRSSSGGGSSGGGGS) and mixed them to-
gether to generate an scFv library of 2 3 107 total clones. To
select for scFvs specific for the PTP1B-CASA mutant, we em-
ployed a subtractive panning strategy (Figure 2A). Addition of
a molar excess of reduced wild-type (WT) PTP1B to the library
in solution would favor enrichment of CASA-specific scFvs
over scFvs that recognize the common epitopes on both the
oxidized and the reduced forms of the enzyme. Initially, we
generated biotinylated CASA mutant for use in subtractive
panning by an in vitro chemical modification. This biotinylation
method, however, adds biotin to free amine groups at random,
and we found that chemical biotinylation caused significant
reduction of PTP activity (Figure 2B). To alleviate this problem,
we took the approach of site-specific homogenous biotinylation
of PTP1B in E. coli by using a biotinylation tag that we fused to
the N terminus of the phosphatase (Figure 2C). Biotinylation of
PTP1B by this method generated a soluble protein and caused
no reduction in activity when compared to the phosphatase
activity of the nonmodified enzyme (Figure 2B). This suggests
that the in vivo biotinylation does not add biotin nonspecifically
to important residues in or around the catalytic site of PTP1B,
and N-terminally biotinylated PTP1B-CASA (NBT-PTP1B-
CASA) was amenable to use for screening for conformation-
sensor antibodies (Figure 2D).
We performed five rounds of subtractive panning using
NBT-PTP1B-CASA in the presence of a molar excess of nonmo-
dified PTP1B-WT. Selective enrichment of phage expressing
PTP1B-CASA-specific scFvs was observed in terms of in-
creased phage output/input ratio after each round of panning.
We observed 1000-fold enrichment of specific scFv-express-
ing phage particles after the fourth round of panning (Figure 2E).
To isolate individual phage particles expressing functional
scFvs, we sequenced 400 phagemid constructs from the en-
riched library. More than 95% of the sequences were full-length
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Figure 1. The Conformation of PTP1B-
CASA Resembles that of PTP1B-OX
(A) View of PTP1B-CASA superimposed onto
PTP1B-OX (sulfenyl-amide species) (PDB code:
1OEM) (Salmeen et al., 2003). (B) View of PTP1B-
CASA superimposed onto wild-type reduced
PTP1B (PDB code: 2HNQ) (Barford et al., 1994a).
In (A) and (B), the view is onto the catalytic site.
(C) and (D) are the same superimpositions as (A)
and (B), respectively, and show close-up views of
the conformational changes at the catalytic site,
indicating that the PTP loop and Tyr46 of the pTyr
loop become similarly solvent-exposed in PTP1B-
OX and PTP1B-CASA.
In all panels, the PTP loop, pTyr loop, WPD loop,
and Q loop of PTP1B-OX are shown as salmon,
light green, yellow, and light blue, respectively.
The equivalent loops for PTP1B-CASA (A and C)
and reduced PTP1B (B and D) are red, dark green,
orange, and blue. The Ca-Cb bond of Tyr46 of the
reduced pTyr loop is obscured by the superim-
position of the oxidized pTyr loop in (B) and (D).
Figures are produced using PyMOL. See also
Table S1.functional scFvs, indicating that the cloning strategy and library
display worked. Interestingly, diversity among the functional
scFv sequences was found to be 70% after the second round
of panning, whereas after the fourth round of panning, it was
20%, suggesting that the library was enriched with specific
scFvs after the panning steps. Sequences were sorted into
groups on the basis of differences in their hypervariable regions.
The selected scFv sequences (Figure S1B) also contain the 6-His
and HA tags at the C termini.
Isolation of Candidate scFvs Specific for PTP1B-OX
We systematically analyzed individual bacterially purified scFvs
from pools of phage enriched after the subtractive panning, by
conducting a screen in solution, in order to preserve the confor-
mational integrity of PTP1B-OX. In this screen we employed a
phosphatase assay to assess the effect of scFv binding on the
activity of PTP1B.
At first, we tested whether any of the scFvs used in this screen
had a direct inhibitory effect on phosphatase activity of PTP1B
under reducing conditions. We observed, as expected, that
none of the scFvs, from a randomly selected batch, had any
such direct effect on activity (Figure 3A). To screen for PTP1B-Cell 147, 185–198, SeOX-specific scFvs, we established condi-
tions under which PTP1B was reversibly
oxidized by H2O2 (Figure 3B). The ability
of individual scFvs to stabilize the revers-
ibly oxidized, inactive conformation of
PTP1B was assessed by the ability of
the scFv to inhibit the reactivation of the
enzyme by reducing agent. Some of the
scFvs demonstrated substantial inhibi-
tion of the restoration of PTP1B activity
following addition of reducing agent (Fig-ure 3C). In particular, scFvs 45 and 57 inhibited the reactivation
by 70%.
To generate the scFvs, we utilized a truncated (1–321) form of
PTP1B, which comprised the catalytic domain. To investigate
further two of the candidate conformation-sensor antibodies
(scFvs 45 and 57), we tested their potential to inhibit reactivation
of a longer form of recombinant PTP1B (1–394) that contained
most of the noncatalytic C-terminal segment that is found in
the protein in vivo. Neither scFv45 nor scFv57 demonstrated
a significant direct inhibition of phosphatase activity of the
reduced, active PTP1B (1–394), whereas, when incubated with
the reversibly oxidized form, both of these scFvs caused almost
complete inhibition of reactivation (Figures 3Dand3E; Figure S2).
These results suggest that these scFvs can sequester oxidized
PTP1B in its inactive conformation, thereby preventing reactiva-
tion by reducing agents with the effect of inhibiting phosphatase
activity.
Candidate scFvs Bound to PTP1B-OX In Vitro
with High Affinity and Specificity
We tested whether the candidate scFvs from the in vitro screen
bound to PTP1B-OX. In a Ni-NTA precipitation experimentptember 30, 2011 ª2011 Elsevier Inc. 187
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Figure 2. Subtractive Panning to Enrich PTP1B-OX-Specific scFvs
(A) Single-chain variable fragments (scFvs) were cloned into the phagemid and transformed to E. coli. Infection with a helper phage (VCSM13) enabled bacteria to
make phage particles expressing the scFvs fused to surface protein pIII. Molar excess (up to 503) of wild-type PTP1B was added under reducing condition,
followed by biotinylated PTP1B-CASA. Phage-scFvs were then isolated by magnetic beads. The phage-scFvs were eluted, amplified, and used for subsequent
rounds of panning.
(B) Phosphatase activity of PTP1B (1–321), N-terminally biotinylated (NBT) in vivo or chemically biotinylated in vitro (WT+B), was measured using 32P-RCML as
the substrate. Chemical biotinylation was performed at three proteins: biotin ratios ([1] = 1:10, [2] = 1:20, and [3] = 1:30). The activity of biotinylated PTP1B was
compared to that of the untagged wild-type enzyme (1–321), which was set as 100%. The error bars represent standard deviation from four phosphatase assays.
(C) PTP1B (1–321) (WT and CASA), N-terminally biotinylated in vivo in E. coli, was purified in a two-step purification scheme.
(D) N-terminally biotinylated PTP1B-CASA mutant (NBT-CASA) or untagged wild-type PTP1B (1B-WT) was incubated with streptavidin-coated magnetic beads,
and biotinylated proteins (and PTP1B) were detected by immunoblot in input (Inp), supernatant (Sup), and precipitated (Ppt) samples.
(E) Enrichment of phage-expressing PTP1B-CASA-specific scFvs was estimated in terms of phage output/input ratio after each round of panning.
See also Figure S1.
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Figure 3. Screening for PTP1B-OX-Specific scFvs
(A) Purified scFvs (750 nM) were incubated with PTP1B (1–321) (7.5 nM) with or without reducing agent TCEP (5 mM), and phosphatase activity was measured
using 100 nM RCML, in which tyrosine was phosphorylated, as the substrate.
(B) PTP1B (1–321) (15 nM) was incubated with increasing concentration of H2O2. Aliquots of H2O2-treated PTP1B (5 nM final) were used in the phosphatase assay
following buffer exchange, without or with TCEP, to observe the inactivation and reactivation of the enzyme, respectively.
(C) PTP1B (1–321) (15 nM) was reversibly oxidized by H2O2 (75 mM) and aliquots (7.5 nM) of this reversibly oxidized PTP1B were incubated with purified scFvs
(750 nM). Reactivation with or without the presence of scFvs was measured by phosphatase assay in the presence of TCEP.
(D) Direct inhibitory effect of scFvs 45 or 57 (750 nM each) were assessed using PTP1B (1–394) (7.5 nM) in a phosphatase assay similar to that in (C).
(E) PTP1B (1–394) (15 nM) was reversibly oxidized with H2O2 (75 mM), and reactivation by TCEP with or without scFvs 45 and 57 was observed by phosphatase
assay.
Error bars show standard deviation from three phosphatase assays. See also Figure S2.in vitro, scFv45 and scFv57 interacted with PTP1B-OX or
PTP1B-CASA but not with reduced PTP1B (Figure 4A). A
dose-response analysis indicated that scFvs 45 and 57 dis-
played IC50s of 19 nM and 10 nM, respectively, for suppressing
the reactivation of PTP1B-OX (Figure 4B). This result is consis-tent with the effects of scFvs 45 and 57 on the activity of
PTP1B (Figure 3). We used surface plasmon resonance (SPR)
to measure the binding constants for the interaction between
scFv45 and PTP1B-OX. Under reducing conditions, PTP1B did
not show any significant binding to scFv45, further confirmingCell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc. 189
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Figure 4. scFv45 Binds Specifically to PTP1B-OX In Vitro
(A) PTP1B (1–321), reduced (1B-R), reversibly oxidized with H2O2 (1B-OX), or with PTP1B-CASA mutant, were incubated with purified scFvs 45 and 57, and the
protein complexes were precipitated with Ni-NTA agarose beads. Equivalent amounts (2.5 ng of PTP1B) of input, supernatant, and eluate were subjected to
immunoblot analysis.
(B) Increasing concentrations of scFvs 45, 57, 34, and 20 (2.5 nM to 1mM) were incubated with PTP1B-OX, and phosphatase activity was measured after adding
TCEP (5 mM). IC50 values for the inhibition of PTP1B reduction and reactivation were determined using the Grafit software. The error bars represent standard
deviation from three phosphatase assays.
(C) Comparative SPR sensogram shows the interaction between scFv45 (500 nM) and either PTP1B-OX (1 mM) or reduced PTP1B (1 mM with 2 mM TCEP)
(PTP1B-R).
(D) Different concentrations of PTP1B-OX were injected on immobilized scFv45 (500 nM) on Ni-NTA sensor chip using BIACORE 2000. The kinetic constants for
binding were calculated with the BIAevaluation 3.1 software.
See also Figure S3.
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Figure 5. scFv45 Displays Specificity for PTP1B-OX over TCPTP-OX
(A) Recombinant TCPTP (1–317) was reversibly oxidized by H2O2 and reactivated by TCEP (5 mM). Phosphatase assay was determined using 100 nM
32P-RCML
and 5 nM of enzyme from each sample.
(B) Purified scFvs (750 nM) were incubated with oxidized TCPTP (7.5 nM), and phosphatase assay was determined in presence of TCEP (5 mM).
Error bars in (A) and (B) show standard deviation from six (A) and three (B) phosphatase assays.
(C) TCPTPwas reversibly oxidizedwith H2O2 and binding with scFv45 was assessed by anti-HA-Agarose pull-down. Equivalent amounts (4 ng of TCPTP) of input,
supernatant, and precipitate were analyzed by immunoblot. As a control, a parallel pull-down was performed with reversibly oxidized PTP1B and scFv45.
See also Figure S4.that scFv45 binds specifically to PTP1B-OX but not to PTP1B in
its reduced, active conformation (Figure 4C). A dose response
between increasing concentrations of PTP1B-OX (50 nM to
10 mM) and a fixed amount of scFv45 (500 nM) indicated that
scFv45 bound to PTP1B-OX with high affinity (dissociation
constant [KD] = 46 nM), and the interaction had a slow off-rate
(Koff = 2.3 3 10
3 s1) (Figure 4D). The interaction between the
PTP1B-CASA mutant and scFv45 was comparable (KD =
52 nM, Koff = 4.6 3 10
3 s1) (Figure S3A). The interaction
between PTP1B-CASA and scFv45 was almost identical with
or without the reducing agent TCEP (Figure S3B), showing that
the presence of the reducing agent does not affect PTP1B-
scFv45 binding per se; rather it is the redox-dependent changes
in conformation of the enzyme that are responsible for the
specific interaction.
TCPTP is the closest relative of PTP1B among the classical
PTP family of enzymes and displays 75% sequence identity
with the catalytic domain of PTP1B (Iversen et al., 2002).
Because of their close structural similarity (Figure S4), the poten-
tial for agents that target PTP1B to display overlapping
specificity toward TCPTP has been a concern. It was shown
previously that TCPTP is reversibly oxidized in mammalian cells,
together with PTP1B, following insulin stimulation (Meng et al.,2004). Therefore, we tested the specificity of scFv45 for
PTP1B-OX over TCPTP. Bacterially purified recombinant TCPTP
was incubated with increasing concentrations of H2O2, and
reactivation by reducing agent was determined by measuring
phosphatase activity (Figure 5A). Incubation with scFv45, or
scFv57, exerted no obvious effect on the reduction and reactiva-
tion of oxidized TCPTP (Figure 5B). In a pull-down experiment
with anti-HA antibody conjugated to agarose beads, we demon-
strated that in vitro-oxidized TCPTP also did not bind to scFv45
(Figure 5C). These results demonstrate that conformation-
specific scFvs to PTP1B-OX did not bind the oxidized, inactive
form of TCPTP, highlighting their selectivity in recognition of
specific epitope(s) on PTP1B-OX.
scFv45 Bound to PTP1B-OX in Mammalian Cells
in Response to Insulin and H2O2
A major advantage of using phage display to generate PTP1B-
OX-specific antibodies is that the selected scFvs can be
expressed inside mammalian cells as functional intracellular
antibodies or ‘‘intrabodies.’’ We observed robust and stable
expression of the PTP1B-OX conformation sensor scFv45 in
293T cells (Figure 6). We generated a ‘‘mini’’ mammalian expres-
sion library by cloning additional individual scFvs into theCell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc. 191
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Figure 6. scFv45 Bound to PTP1B-OX in H2O2- and Insulin-Treated 293T Cells
(A) scFv45-expressing 293T cells were treated with H2O2 (1 mM) or NAC (20 mM), and cell lysates were prepared with or without TCEP (2 mM). From 1 mg of cell
lysate, scFv45 was immunoprecipitated and binding to PTP1B, under oxidized or reduced conditions, was detected by immunoblot.
(B) In a similar experiment, 293T cells expressing scFv45 were treated with insulin (25 nM), H2O2 (1 mM), or NAC (20mM), and intrabody was immunoprecipitated
from 1 mg of lysate. The membrane was stripped and reprobed with anti-TCPTP mouse monoclonal antibody (CF4).
(C) Cos1 cells transfected with scFv45 or scFv20 were treated with insulin (25 nM), or H2O2 (1 mM) or left untreated. Fixed cells were processed for immuno-
fluorescence and visualized by confocal microscopy with oil immersion (633).
(D) Colocalization of PTP1B and scFv45 was analyzed by Zeiss (LSM 710) Colocalization Viewer Software. The numeric range for colocalization is set as 0–1,
where ‘‘0’’ indicates no colocalization and ‘‘1’’ indicates colocalization of all pixels. Error bars indicate standard deviation from colocalization analysis of 25
individual cells.
See also Figure S5.pCDNA3.2/V5-GWD-TOPO vector from their corresponding
phagemid constructs. Using a Ni-NTA pull-down assay with
equivalent amounts of scFv-transfected, H2O2-treated lysates,
we identified more candidate scFvs that bound to endogenous
PTP1B-OX and did not display any binding to PTP1B under
reducing conditions (Figure S5). Interestingly, consistent with
selective binding to PTP1B-OX in vitro, scFv45 expressed as
an intrabody also bound to PTP1B-OX. The negative control
scFv20, which did not stabilize and inhibit reactivation of
PTP1B-OX in vitro (Figure 3), showed no binding to PTP1B-OX
in cells. This indicates that PTP1B undergoes similar oxidation-
induced conformational change in mammalian cells when192 Cell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc.treated with H2O2, and scFvs that bind PTP1B-OX in vitro were
also functional when expressed in 293T cells.
Furthermore, we demonstrated that scFv45 efficiently immu-
noprecipitated PTP1B-OX from cells treated with H2O2 but
showed little or no interaction with PTP1B when cells were
treated under reducing conditions (Figure 6A). These results
are consistent with the earlier observation in vitro that scFv45
recognized distinct conformational epitopes formed by oxidation
of PTP1B by H2O2. Stimulation of cells with insulin causes rapid
and transient oxidation and inhibition of PTP1B, which facilitates
increased phosphorylation of the insulin receptor b subunit (Ma-
hadev et al., 2001; Meng et al., 2004). We observed that scFv45
immunoprecipitated PTP1B from lysates of transfected 293T
cells that were treated with insulin (Figure 6B). In cells that
were untreated or were processed under reducing conditions,
such interaction was absent. We demonstrated that scFv45
bound specifically to PTP1B-OX but not to TCPTP-OX in vitro
(Figure 5). In mammalian cells, scFv45 displayed similar speci-
ficity toward endogenous PTP1B-OX and did not interact with
endogenous TCPTP following either insulin stimulation or H2O2
treatment (Figure 6B).
In order to visualize the interaction between PTP1B-OX and
scFv45 in mammalian cells, we used immunofluorescence to
examine whether there was colocalization of PTP1B and
scFv45 in Cos1 cells following insulin stimulation or H2O2 treat-
ment. Significant colocalization between PTP1B and scFv45
was observed, whereas such colocalizationwas absent between
the negative control scFv20 and PTP1B (Figures 6C and 6D).
scFv45 Enhanced and Prolonged Tyrosine
Phosphorylation in 293T Cells in Response to Insulin
in an ROS-Dependent Manner
We demonstrated that the conformation-sensor antibody
scFv45 sequestered reversibly oxidized PTP1B and prevented
reactivation of the enzyme. Therefore, we tested whether such
sequestration of a negative regulator of insulin receptor kinase
had an impact on downstream signaling in mammalian cells.
When 293T cells in which scFv45 was overexpressed were stim-
ulated with insulin, the insulin receptor b subunit (IRb) and IRS-1
displayed enhanced and sustained tyrosine phosphorylation in
comparison to cells without the ectopically expressed intrabody
or with the negative control intrabody scFv20 (Figure 7A). Similar
stimulatory effects of scFv45 were observed on insulin- and
EGF-induced signaling in HeLa cells (Figure S7). Interestingly,
when catalase, the enzyme that catalyzes the decomposition
of H2O2 to water and oxygen, was co-overexpressed in the
cytosol together with scFv45 or the negative control scFv20,
the enhanced tyrosine phosphorylation of both IRb and IRS-1
was diminished (Figure 7A and Figure S6B).
Furthermore, we used a phospho-site-specific antibody to
focus on the tandem residues (Y1162/Y1163) of the IRb activa-
tion loop, which have been identified as substrates of PTP1B
(Salmeen et al., 2000). Again, expression of scFv45 led to
enhanced and sustained insulin-induced phosphorylation of
these residues, and this effect was attenuated by coexpression
with catalase (Figure 7B). In contrast, any effects of scFv45 on
the phosphorylation of Y1328, from the C terminus of IRb,
were much less pronounced, suggesting preferential recognition
of individual phosphorylation sites in IRb by PTP1B (Figure S6C).
scFv45 Caused Increased AKT Phosphorylation
in Response to Insulin
In order to test for effects of the intrabody on downstream
signaling, we used a phospho-specific antibody that recognizes
phosphorylation of T308 in PKB/AKT as a read-out. Cells overex-
pressing scFv45 displayed enhanced and sustained PKB/AKT
phosphorylation when treated with insulin (Figure 7A). This effect
was maintained over a time course of 60 min (Figure 7C). When
catalase was overexpressed together with scFv45, the stim-
ulatory effects of the intrabody on PKB/AKT activation wereablated (Figure 7C). Furthermore, expression of the negative
control scFv20 hadnoeffect onPKB/AKT activation (FigureS6A).
We found no change in PTP1B expression in any of these con-
ditions, indicating that changes in the levels of PTP1B do not
underlie the enhancement in signaling. Overall, our data are
consistent with a model in which scFv45 binds and stabilizes
endogenous PTP1B-OX, thereby effectively attenuating PTP1B
activity and removing its inhibitory effect, with resulting enhance-
ment of insulin signaling.
DISCUSSION
Dysfunctional insulin signaling results in insulin resistance, which
is ultimately associated with metabolic syndromes, including
type 2 diabetes and obesity (Saltiel and Kahn, 2001). Insulin
induces activation of the insulin receptor kinase through auto-
phosphorylation (Saltiel and Pessin, 2002). Recruitment of
IRS-1 to the receptor triggers activation of phosphatidylinositol
3-kinases (PI3K) and the stimulation of downstream effectors,
such as phosphatidylinositol-dependent kinase 1 (PDK1) and
PKB/AKT, leading to translocation of glucose transporter 4
(GLUT4) and glucose uptake, and inactivation of glycogen-syn-
thase kinase 3 (GSK3) (Bryant et al., 2002). PTP1B is an impor-
tant negative regulator of signaling; it dephosphorylates the
tandem tyrosine residues (pY1162/pY1163) of activated IRb
(Salmeen et al., 2000) and IRS-1 (Goldstein et al., 2000), exerting
a major influence on the duration and amplitude of the cellular
response to insulin. Consequently, regulation of PTP1B activity
would be expected to facilitate fine-tuning of insulin-induced
signaling. Our data highlight the importance of reversible oxida-
tion of PTP1B as one such regulatory mechanism and validate
stabilization of the inactive phosphatase conformation as a
potential therapeutic strategy.
A feature of the microbicidal function of phagocytes is the
reduction of molecular oxygen by a NADPH oxidase (NOX)
enzyme system, which generates superoxide (O2
) that is con-
verted to H2O2 (Bokoch and Zhao, 2006). The NOX enzymes
are multiprotein complexes, the activity of which is tightly con-
trolled. Nonphagocytic cells are now also known to contain
similar NOX enzymes, which are capable of generating ROS
but at lower levels than those associated with the killing of
invading micro-organisms (Lambeth, 2004). Controlled produc-
tion of ROS, such as H2O2, has been observed in nonphagocytic
cells in response to a number of ligands that act through receptor
tyrosine kinases (Bae et al., 1997; Mahadev et al., 2001; Meng
et al., 2004; Sundaresan et al., 1995). PTPs have been identified
as direct targets of ROS, the presence of an essential low pKa
catalytic cysteine residue rendering them exquisitely sensitive
to oxidation and inactivation (Rhee, 2006). In particular, PTP1B
is transiently inactivated by reversible oxidation of the active-
site cysteine following insulin-induced generation of H2O2 in
mammalian cells (Mahadev et al., 2001; Meng et al., 2004).
PTP1B is targeted to the cytoplasmic face of membranes of
the ERwhere it functions in a ‘‘dephosphorylation compartment’’
in which it acts to terminate signaling from receptor PTKs that
have undergone endocytosis following ligand stimulation (Eden
et al., 2010; Haj et al., 2002). This ER localization exposes
PTP1B essentially to the entire cytoplasm, and there haveCell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc. 193
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In (A)–(C), cells transiently expressing scFv45 or scFv20 or cotransfected with scFv45 and catalase were treated with insulin (25 nM) for the indicated times, and
total cell lysate (60 mg in A and C and 80 mg in B) was subjected to immunoblot analysis of the indicated proteins.
See also Figure S6 and Figure S7.been reports of it exerting its effects from the perinuclear
compartment (Romsicki et al., 2004) all the way to interactions
with substrate at the plasma membrane (Nievergall et al.,
2010). It has been suggested that PTP1B exists in spatially194 Cell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc.distinct subpopulations on the surface of the ER, some of which
are associated with a reversible low-activity state that may
define different signaling functions (Yudushkin et al., 2007).
Reversible oxidation would be one mechanism to achieve this
compartmentalization. Interestingly, NOX4, which is responsible
for oxidation of PTP1B in response to insulin (Mahadev et al.,
2004), was reported to colocalize with PTP1B on ERmembranes
(Martyn et al., 2006), and this colocalization was essential for
signal-induced oxidation and inactivation of PTP1B (Chen
et al., 2008). The reversibility of oxidation and inactivation is
essential for this covalent modification to represent a means
for regulation of tyrosine phosphorylation-dependent signaling.
Our original structure of oxidized PTP1B suggests a molecular
mechanism by which such reversibility may be achieved.
We observed that oxidation induced profound conformational
changes in PTP1B, in which the active-site cleft opens up both to
expose critical catalytic residues and to present new binding
surfaces on the protein (Salmeen et al., 2003). Upon soaking
PTP1B crystals with stoichiometric quantities of H2O2, an
unstable sulfenic acid (Cys–S-OH) is generated initially, which
then undergoes a rapid condensation reaction to produce a
cyclic sulfenyl-amide species (Salmeen et al., 2003). This modi-
fication, previously undetected in proteins, was generated when
a covalent bond formed between the side-chain S atom of
Cys215 and the main-chain N atom of Ser216, and resulted in
disruption of critical H bonds that maintain the stability of the
active-site cleft. Independently, Van Montfort et al. reported
the formation of the same structure when PTP1B crystals were
soaked with 2-phenyl-isoxazolidine-3,5-dione, which is a per-
oxide generator and, thereby, an inhibitor of PTP1B (Tjernberg
et al., 2004; van Montfort et al., 2003). Incubation of crystals
of the sulfenyl-amide form of PTP1B with reducing agent led
to a quantitative reduction of the enzyme and a return to the
catalytically active conformation. Thus, formation of this cyclic
sulfenyl-amide intermediate may protect the enzyme from irre-
versible inactivation by higher-order oxidation and, by present-
ing the signature motif that contains the active-site Cys residue
on the surface of the protein, may facilitate reactivation by
reducing agents in the cell (Tonks, 2005). We exploited the
new binding surfaces that are unique to the oxidized form of
the enzyme to generate scFv antibodies that were selective for
the oxidized conformation of PTP1B in vitro. Our data illustrate
that these scFvs also bound to PTP1B in mammalian cells in
response to insulin-mediated ROS production or treatment
with exogenous H2O2. These results indicate that the reversible
redox modification involving formation of a cyclic sulfenyl-amide
also occurs in cells, thereby removing concerns that the struc-
ture was an artifact of crystallization and focusing attention on
its potential physiological importance.
Our study illustrates the importance of endogenously
produced H2O2 and concomitant reversible inhibition of PTP1B
activity in augmenting insulin signaling. We demonstrated that
the conformation-sensor antibody scFv45 bound to the oxidized
conformation of PTP1B that is produced following treatment with
either insulin or H2O2, but no interaction was observed in
untreated cells. Furthermore, scFv45 enhanced and prolonged
tyrosine phosphorylation of both IRb and IRS-1, and this effect
was transduced downstream to yield a sustained increase in
PKB/AKT phosphorylation and activation. Interestingly, scFv45
did not cause changes in basal tyrosine phosphorylation or
downstream signaling, indicating that it does not function as an
insulin mimetic to promote basal signaling in the absence ofhormone, rather it functions as an insulin sensitizer. This
enhancement of insulin-induced signaling was attenuated when
scFv45 was coexpressed with catalase, which has been shown
previously to degrade H2O2 in cells (Irani et al., 1997), indicating
that H2O2 production is required for the antibodies to exert their
stimulatory effects on signaling. Therefore, our data suggest
that insulin stimulates a rise in intracellular H2O2 that transiently
oxidizes and inactivates PTP1B, tipping the delicate balance
between PTP and PTK activity in favor of the kinase, to promote
signaling. Expressionof scFv45stabilizes theoxidizedconforma-
tion of PTP1B, delaying its reduction and reactivation and further
shifting the balance toward tyrosine phosphorylation, thereby
promoting enhanced and sustained insulin signaling.
Antibody phage display is a powerful technique that allows
target antigens to be preserved in their native state and, there-
fore, has the potential to yield antibodies that can recognize
specific conformations of a target protein (Marasco, 1997).
Furthermore, it permits the resulting antibodies to be expressed
in cells as intrabodies, such as the scFvs used in this study, in
which the variable heavy and light chains are linked directly,
without the need for disulphide bonds. Therefore, not only are
these intrabodies stable and functional in the overall reducing
environment of the cell, but also the ability to express them over-
comes the problems associatedwith delivering whole antibodies
across the plasmamembrane (Cardinale and Biocca, 2008). One
example is the generation of intrabodies that detect specifically
GTP-bound Rab6 in the Golgi and with which the dynamics of
Rab6-GTP-positive transport intermediates could be followed
by immunofluorescence (Nizak et al., 2003). The screening pro-
cedures in phage display permit great flexibility in selection
conditions. In our study, we generated a library from a donor
immunized with the mutant form of PTP1B that is locked in the
oxidized conformation. We were able to enrich for conforma-
tion-sensor antibodies that recognized this structure specifically
by screening with oxidized PTP1B in the presence of a molar
excess of the reduced enzyme. Not only did the intrabodies
recognize and stabilize the inactive conformation induced by
a unique posttranslational inhibitory modification on PTP1B,
thereby potentiating insulin signaling, but also they did so with
remarkable specificity. There are a number of gene duplications
that occurred in the evolution of the PTP family. One such event
generated two closely related phosphatases, PTP1B and
TCPTP, and one spliced isoform of TCPTP is localized to the
ER in a similar manner to PTP1B (Iversen et al., 2002). In fact,
insulin induces the oxidation of TCPTP (Meng et al., 2004), and
there are data suggesting distinct, yet complementary roles for
PTP1B and TCPTP in regulation of insulin signaling (Galic
et al., 2005). Nevertheless, the scFvs generated in this study
did not recognize TCPTP, highlighting their potential as specific
probes of PTP1B function. Although TCPTP displays 75%
sequence identity to PTP1B in its core catalytic domain, rising
to 85% when conservative substitutions are considered, there
are differences in surface residues between the two PTPs (Fig-
ure S4) that may contribute to this specificity.
Quite apart from their significance as reagents, these anti-
bodies may influence strategies for development of PTP1B-
directed therapeutics. The phenotype of the knockout mouse,
together with structural and biochemical data from variousCell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc. 195
groups, has established PTP1B as a key regulator of insulin and
leptin signaling (Tonks, 2003). Consequently, it became a highly
prized target in the pharmaceutical industry for therapeutic inter-
vention in diabetes and obesity. Although there have been major
programs in industry focused on developing small-molecule
inhibitors of PTP1B, these efforts have been frustrated by tech-
nical challenges arising from the chemical properties of the PTP
active site (Zhang and Zhang, 2007). The susceptibility of PTPs
to oxidation causes problems in high-throughput screens. In
addition, the tendency of potent active-site-directed inhibitors
to be highly charged, such as nonhydrolyzable pTyr mimetics,
presents problems with respect to oral bioavailability that limit
drug development potential. Nevertheless, considering the
importance of PTP1B as a therapeutic target, there is a compel-
ling need to explore innovative ideas and schemes to target the
enzyme for generating novel, potent, and selective inhibitors.
The profound conformational change at the active site induced
by oxidation provides new sites for developing chemical scaf-
folds or small-molecule inhibitors that could recognize the
reversibly oxidized conformation of PTP1B and lock it in the inac-
tive state. Stabilization of the inactive PTP1B-OX conformation
may potentiate insulin signaling in a manner similar to inhibition
of the catalytically active form of the enzyme, analogous to stabi-
lization of the inactive form of p210 BCR-ABL by Gleevec/Imati-
nib (Schindler et al., 2000). Also, if one assumes that in respond-
ing to insulin the cell targets for oxidation the pool of PTP1B that
is important for regulation of the signaling response, then this
strategy will also target that pool specifically, possibly also
reducing complications of side effects that may accompany inhi-
bition of the native enzyme as a whole. Furthermore, most potent
active-site-directed inhibitors of PTP1B show some degree of
inhibition of TCPTP as well (Johnson et al., 2002). TCPTP is
essential for normal hematopoiesis, and TCPTP null mice die
as a result of hematopoietic defects within weeks of birth (You-
Ten et al., 1997). Consequently, there was concern in drug
discovery efforts to minimize the effects on TCPTP of any
PTP1B inhibitors. The properties of our scFv intrabodies alleviate
this concern. Problems of delivery to the appropriate tissues
represent serious hurdles to the use of such intrabodies as ther-
apeutic agents. Nevertheless, our data indicate that if it is
possible to stabilize the oxidized, inactive form of PTP1B with
an appropriate small molecule that mimics the effects of these
antibodies, then this could provide an alternative strategy for
PTP-directed drug development that would circumvent the diffi-
culties that are faced when targeting the PTP-active site with
highly charged inhibitors.EXPERIMENTAL PROCEDURES
Construction of scFv Phage Display Library
Chickens were immunized with purified PTP1B-CASA. Total RNAwas isolated
from the spleen and bonemarrowof the immunized animals. First-strand cDNA
was synthesized from the total RNA and used for PCR amplification of the VL
and VH genes, which were combined to form a full-length scFv construct.
Screening Individual scFvs as Conformation-Sensor Antibodies
to PTP1B-OX
The scFv library was mixed with 10- to 50-fold molar excess of wild-type
PTP1B over the biotinylated PTP1B-CASA under reducing conditions.196 Cell 147, 185–198, September 30, 2011 ª2011 Elsevier Inc.Phage-scFvs bound to biotinylated PTP1B-CASA were captured by streptavi-
din-coated magnetic beads, eluted under acidic conditions, neutralized,
and amplified. A total of five rounds of panning were performed accordingly.
Individual scFvs were expressed without the pIII fusion component in a non-
suppressor E. coli (TOP10F0 ) and purified with Ni-NTA. Recombinant PTP1B
was reversibly oxidized and inactivatedwith H2O2, then incubated with purified
scFvs. The effect of individual scFvs on stabilizing the reversibly oxidized
conformation was assessed by phosphatase assay under reducing
conditions.
Effect of PTP1B-OX-Specific Intrabodies on Insulin Signaling
Intrabody constructs for scFv45 or scFv20 were transfected in 293T cells,
which were stimulated with insulin for various times. Total proteins in the cell
lysates were separated by SDS-PAGE, and global tyrosyl phosphorylation
was detected by anti-phosphotyrosine antibody 4G10. To detect specific
tyrosyl phosphorylation of the IRb subunit, we used rabbit polyclonal anti-
insulin receptor [pYpY1162/1163] phospho-specific antibody. To test the effect
of suppressing H2O2 levels on intrabody function, catalase was ectopically
coexpressed with scFv45. Catalase expression was detected in the cell
samples with anti-catalase rabbit polyclonal antibody. Phosphorylation of
the AKT activation loop at residue threonine 308 (T308) was observed with
phospho-specific antibody.
Details of methods and materials are described in the Extended Experi-
mental Procedures in the Supplemental Information available online.ACCESSION NUMBERS
Crystallographic coordinates and structure factors of the PTP1B-CASA
mutant have been deposited with the PDB with accession ID codes 3zv2
and r3zv2sf, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, one table, and Supplemental References and can be found with this
article online at doi:10.1016/j.cell.2011.08.036.
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